ABSTRACT
Treatment options for metastatic osteosarcomas are scarce. Following failure of standard first line therapy, patients who relapse present a challenging treatment dilemma, and have a poor prognosis. Surgical removal of all metastases is essential. A retrospective analysis of patients with metastatic osteosarcomas was conducted in 15 French Sarcoma Group centers. From January 2009 to December 2018, we identified 120 adult patients; 36 with synchronous and 84 with metachronous metastases with 74 males and 46 females. Mean age was 30 years (18-53). Metastatic sites were lung, bone and other in 91, 11 and 24 patients, respectively. Mean time to first metachronous metastases was 22 months (4-97). All patients except 13 (10.8%) with metachronous metastases received a first line systemic treatment for relapse, and 39 patients (32.5%) were included in a clinical trial. Eighty-one patients (67.5%) had local treatment of distant metastases. Median progression free survival (PFS) and overall survival (OS) were 5.5 (95% CI 4.6-6.4) and 20.5 months (95% CI 13.2-27.7) respectively for the overall group. In multivariate analysis, more than five metastases, time to first metastases <24 months, were statistically significant negative prognostic factors for OS and PFS (P = .002, ≤.001 and P = .006, ≤.001, respectively). Surgery of metastases was associated with better prognosis on OS and PFS (P = .001 and .037, respectively). The presence of bone metastases was a negative prognostic factor on OS but not on PFS (P = .021). In reference sarcoma centers, relapsed osteosarcoma patients with more than one metastasis commonly receive more than one line of systemic therapy, and are included in clinical trial if available.
Subject(s)
Bone Neoplasms/pathology , Neoplasms, Multiple Primary/secondary , Neoplasms, Second Primary/secondary , Osteosarcoma/pathology , Adolescent , Adult , Bone Neoplasms/mortality , Bone Neoplasms/therapy , Female , Humans , Male , Middle Aged , Osteosarcoma/mortality , Osteosarcoma/therapy , Retrospective Studies , Young AdultABSTRACT
BACKGROUND: A subset of metachronous colon cancer recurrence manifests as peritoneal metastases (PM). Risk factors for metachronous PM recurrence are not well-defined in patients with stage II or III colon cancers after curative resection and standard adjuvant treatments. METHODS: Population data from the California Cancer Registry for patients with Stage II or III colon cancer were collected between 2004 and 2012. Multivariate analysis was used to identify factors associated with metachronous PM. RESULTS: Of the 2077 patients with stage II or III colon cancer, female patients (odds ratio [OR] = 1.84, p = 0.02), T4 primary tumor (OR = 2.36, p = 0.02), mucinous (OR = 3.97, p < 0.01) or signet-ring histology (OR = 6.01, p = 0.01), and right-sided cancer (OR = 2.2, p < 0.01) were found with increased risk of metachronous isolated PM recurrence after curative resection. Median survival after diagnosis for patients without PM recurrence was 22 months, compared with 12 months for PM recurrence (p < 0.001). CONCLUSION: PM recurrence groups have a worse overall survival than patients with recurrent disease in other sites. A better understanding of the tumor biology and molecular characteristics of colon cancers likely to recur as PM is needed to explain behavior and identify potential targeted therapy.
Subject(s)
Colectomy/adverse effects , Colonic Neoplasms/surgery , Neoplasm Recurrence, Local/pathology , Neoplasms, Second Primary/secondary , Peritoneal Neoplasms/secondary , Aged , Colonic Neoplasms/pathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Neoplasm Staging , Neoplasms, Second Primary/epidemiology , Peritoneal Neoplasms/epidemiology , Retrospective Studies , Risk Factors , Survival RateABSTRACT
OBJECTIVE: We compared outcomes after surgery or stereotactic body radiotherapy (SBRT) among patients with metachronous primary lung cancer (MPLC). METHODS: Patients with MPLC were treated with either surgery (2008-2018) or SBRT (2010-2018). We used propensity score matching (PSM) to reduce bias from various clinicopathological factors. MPLC was defined by the Martini and Melamed criteria. RESULTS: Of 77 patients, 51 underwent surgery and 26 received SBRT. Most median clinicopathological characteristics did not significantly differ between the surgery and SBRT groups (male sex: 67% vs 65%; age: 73 vs 77 years; time after first surgery: 6.2 vs 4.7 years; lobectomy as first procedure: 82% vs 85%; second tumor size: 11 vs 12 mm; clinical stage I: 96% vs 100%; CEA: 2.9 vs 3.0 ng/ml). However, the surgery group had significantly more ipsilateral second tumors (n = 71, 58%, P = 0.003), better performance status (P = 0.03), and preserved lung function (P = 0.02). Surgery, thus, tended to be selected for patients with good physical function and for the MPLC in the contralateral side. Five-year overall survival did not significantly differ between the surgery and SBRT groups, either before PSM (86.5% vs 65.8%, P = 0.24, log-rank) or after PSM (100% vs 84.4%, P = 0.73). CONCLUSIONS: Surgery and SBRT for MPLC patients are safe and feasible treatments with similar outcomes. However, this finding should be verified by a random controlled trial with a larger study cohort.
Subject(s)
Carcinoma, Non-Small-Cell Lung/therapy , Lung Neoplasms/therapy , Neoplasms, Second Primary/therapy , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/secondary , Female , Humans , Japan , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Neoplasm Staging , Neoplasms, Second Primary/mortality , Neoplasms, Second Primary/secondary , Propensity Score , Radiosurgery , Survival AnalysisABSTRACT
BACKGROUND: Modern radiation techniques have led to significant improvements in intracranial disease control and overall survival (OS) for metastatic renal-cell carcinoma (mRCC) patients diagnosed with brain metastases (BM). The impact of systemic therapy in patients developing mRCC BM remains undercharacterized. PATIENTS AND METHODS: We performed a retrospective cohort study of mRCC patients diagnosed with BM. Patients were grouped as having either metachronous BM (ie, ≥ 3 months from mRCC diagnosis) or synchronous BM (ie, < 3 months from mRCC diagnosis). Details of patient demographics, BM, systemic therapy, and outcomes were extracted. Statistical analysis comprised chi-square tests, analysis of variance, and Kaplan-Meier method to characterize survival outcomes. RESULTS: Seventy-four patients were identified (40 at ≥ 3 months from mRCC diagnosis and 34 at < 3 months from mRCC diagnosis) of which 72 (97%) received local therapy for their BM. Median (interquartile range [IQR]) duration while first line treatment was longer at 7.8 (3.6-17.0) versus 5.1 (3.3-12.6) in patients with metachronous BM versus patients with synchronous BM (P = 0.6), respectively. After BM diagnosis, the metachronous BM cohort continued to receive the same systemic therapy for a median (IQR) duration of 1.9 (0.4-5.5) months, with eventual change most commonly the result of extracranial disease progression. Median (IQR) OS from mRCC diagnosis favored metachronous BM patients versus synchronous BM patients, at 64.2 (31.4-not yet reached) versus 22.4 (9.7-34.1) months (P = .003), respectively. However, this was not significantly different from the time of BM diagnosis, with median (IQR) survival of 20.6 (9.2-31.2) versus 15.7 (11.6-not yet reached) months (P = .95), respectively. CONCLUSION: Prolonged OS was found for mRCC patients with BM that presented either metachronously or synchronously. For patients diagnosed with metachronous BM, the development of BM may be an early sign of systemic therapy failure.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Neoplasms/mortality , Carcinoma, Renal Cell/mortality , Kidney Neoplasms/mortality , Neoplasms, Multiple Primary/mortality , Neoplasms, Second Primary/mortality , Aged , Brain Neoplasms/drug therapy , Brain Neoplasms/secondary , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/pathology , Female , Follow-Up Studies , Humans , Kidney Neoplasms/drug therapy , Kidney Neoplasms/pathology , Male , Middle Aged , Neoplasms, Multiple Primary/drug therapy , Neoplasms, Multiple Primary/secondary , Neoplasms, Second Primary/drug therapy , Neoplasms, Second Primary/secondary , Prognosis , Retrospective Studies , Survival RateABSTRACT
Metachronous mediastinal and lung metastases (MMLM), important sources of morbidity and mortality, in people with head and neck cancer (HNC) have received little attention. Between 1980 and 2004, 37 patients with treated HNC and MMLM diagnosed on follow-up imaging (with histological confirmation in 14 cases) were identified. The median interval from diagnosis of HNC to the appearance of MMLM was 14.5 months. The overall median survival was 4 months, and the 1-year crude survival rate (CSR) was 16%. A meaningful difference in the 1-year CSRs between the palliative radiation treated and untreated subjects (39% and 4%, respectively, p < 0.01) was observed. Because associated costs of health care utilization are considerable, and yet survival is limited, optimum management of MMLM-HNC with improvement of prognosis remains a challenge.
Subject(s)
Head and Neck Neoplasms/pathology , Lung Neoplasms/secondary , Mediastinal Neoplasms/secondary , Neoplasms, Second Primary/secondary , Squamous Cell Carcinoma of Head and Neck/pathology , Aged , Combined Modality Therapy , Female , Follow-Up Studies , Head and Neck Neoplasms/therapy , Humans , Lung Neoplasms/therapy , Male , Mediastinal Neoplasms/therapy , Middle Aged , Neoplasms, Second Primary/therapy , Prognosis , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck/therapyABSTRACT
PURPOSE: To report that metastatic choroidal melanoma (systemic and intraocular) can respond to systemic immunotherapy. METHODS: In 2010, a 64-year-old woman with a choroidal melanoma was treated with palladium-103 plaque brachytherapy. Developing 2.5 years later, radiation maculopathy was suppressed with periodic intravitreal anti-vascular endothelial growth factor injections for five additional years. Development of a new, discrete choroidal melanoma in the same eye prompted radiographic imaging of the orbits, abdomen/pelvis, and chest. Multi-organ metastasis in the eye, the liver, and nodes was treated with systemic combination immunotherapy with ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) intravenous every 3 weeks for four cycles followed by nivolumab (3 mg/kg) intravenous every 4 weeks as maintenance. Subsequent ophthalmic and systemic surveillance were performed. RESULTS: All sites of metastases were found to regress on systemic immunotherapy. For example, ophthalmic ultrasound imaging revealed that the intraocular metastasis was reduced from 6.6 to 1.5 mm in thickness. Synchronously, serial radiographic imaging revealed progressive shrinkage and disappearance of hepatic and nodal metastasis (except for one gastrohepatic node). However, combination stereotactic body radiation therapy (30 Gy) with nivolumab maintenance was found to induce a significant reduction in this remaining node. Continued periodic intraocular anti-vascular endothelial growth factor therapy has suppressed her radiation maculopathy resulting in 20/25 vision, now 8 ½ years after initial plaque therapy. CONCLUSION: This case shows that metastatic choroidal melanoma can present in the same eye as the primary tumor. It also shows that systemic immunotherapy can control both ocular and systemic metastases as well as prolong both life and sight.
Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Choroid Neoplasms/therapy , Immunotherapy/methods , Liver Neoplasms/therapy , Lymphatic Metastasis/therapy , Melanoma/therapy , Neoplasms, Second Primary/therapy , Brachytherapy/methods , Choroid Neoplasms/diagnostic imaging , Choroid Neoplasms/pathology , Female , Follow-Up Studies , Humans , Ipilimumab/therapeutic use , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/secondary , Melanoma/diagnostic imaging , Melanoma/secondary , Middle Aged , Neoplasms, Second Primary/diagnostic imaging , Neoplasms, Second Primary/secondary , Nivolumab/therapeutic use , Positron Emission Tomography Computed Tomography , Treatment Outcome , UltrasonographyABSTRACT
Childhood cancer survivors (CCSs) from high-grade malignancies, such as high-risk neuroblastoma, have been increased, and second malignant neoplasm, becomes a serious problem for CCSs. However, detailed reports about rare types of second cancer such as gastric cancer remain limited. We herein reported a female patient who developed diffuse type gastric carcinoma after 21 years from completion of treatment to high-risk neuroblastoma. We reviewed the previous cohort studies for second gastrointestinal cancer in CCSs and the case reports with second gastric carcinoma for CCSs. We presumed second gastric cancer was refractory for CCSs as well as for adult cancer survivors.
Subject(s)
Neoplasms, Second Primary/secondary , Neuroblastoma/pathology , Stomach Neoplasms/secondary , Adult , Cancer Survivors , Fatal Outcome , Female , Humans , Neoplasms, Second Primary/therapy , Neuroblastoma/therapy , Stomach Neoplasms/therapyABSTRACT
BACKGROUND: Approximately 25% of patients with colorectal cancer (CRC) will have liver metastases classified as synchronous or metachronous. There is no consensus on the defining time point for synchronous/metachronous, and the prognostic implications thereof remain unclear. The aim of the study was to assess the prognostic value of differential detection at various defining time points in a population-based patient cohort and conduct a literature review of the topic. METHODS: All patients diagnosed with CRC in the counties of Stockholm and Gotland, Sweden, during 2008 were included in the study and followed for 5 years or until death to identify patients diagnosed with liver metastases. Patients with liver metastases were followed from time of diagnosis of liver metastases for at least 5 years or until death. Different time points defining synchronous/metachronous detection, as reported in the literature and identified in a literature search of databases (PubMed, Embase, Cochrane library), were applied to the cohort, and overall survival was calculated using Kaplan-Meier curves and compared with log-rank test. The influence of synchronously or metachronously detected liver metastases on disease-free and overall survival as reported in articles forthcoming from the literature search was also assessed. RESULTS: Liver metastases were diagnosed in 272/1026 patients with CRC (26.5%). No statistically significant difference in overall survival for synchronous vs. metachronous detection at any of the defining time points (CRC diagnosis/surgery and 3, 6 and 12 months post-diagnosis/surgery) was demonstrated for operated or non-operated patients. In the literature search, 41 publications met the inclusion criteria. No clear pattern emerged regarding the prognostic significance of synchronous vs. metachronous detection. CONCLUSION: Synchronous vs. metachronous detection of CRC liver metastases lacks prognostic value. Using primary tumour diagnosis/operation as standardized cut-off point to define synchronous/metachronous detection is semantically correct. In synchronous detection, it defines a clinically relevant group of patients where individualized multimodality treatment protocols will apply.
Subject(s)
Colonic Neoplasms/pathology , Liver Neoplasms/secondary , Neoplasms, Multiple Primary/secondary , Neoplasms, Second Primary/secondary , Adult , Aged , Aged, 80 and over , Colonic Neoplasms/surgery , Female , Humans , Liver Neoplasms/surgery , Male , Middle Aged , Neoplasm Staging , Neoplasms, Multiple Primary/surgery , Neoplasms, Second Primary/surgery , Survival RateABSTRACT
A 65-year-old woman was referred with an incidental finding of a flurodeoxyglucose-avid uterine lesion, following excision of a local lung adenocarcinoma. MRI had features concerning for an atypical fibroid or smooth muscle tumour of uncertain malignant potential. She underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy. Histopathology demonstrated a leiomyoma infiltrated with adenocarcinoma consistent with a secondary lesion from the lung cancer. Among the small number of cases of uterine metastases of extra-pelvic primary cancers reported in the literature, those from lung cancers are very rare. Concerning features for an atypical fibroid included the patient's age and postmenopausal status, as well as positron emission tomography and MRI findings. A metastatic secondary cancer was not suspected. Diagnosis was only made after histopathological examination. This case represents a very unusual cause of a uterine mass. It demonstrates the importance of thorough preoperative work-up and accurate histopathological assessment.
Subject(s)
Adenocarcinoma of Lung/secondary , Leiomyoma/pathology , Lung Neoplasms/pathology , Neoplasms, Second Primary/pathology , Uterine Neoplasms/secondary , Adenocarcinoma of Lung/diagnostic imaging , Aged , Diagnosis, Differential , Female , Humans , Hysterectomy , Incidental Findings , Leiomyoma/diagnostic imaging , Leiomyoma/surgery , Magnetic Resonance Imaging , Neoplasms, Second Primary/diagnostic imaging , Neoplasms, Second Primary/secondary , Neoplasms, Second Primary/surgery , Positron-Emission Tomography , Postmenopause , Salpingo-oophorectomy , Treatment Outcome , Uterine Neoplasms/diagnostic imaging , Uterine Neoplasms/surgeryABSTRACT
BACKGROUND: Metachronous renal cell carcinoma after radical nephrectomy is extremely rare. Renal cell carcinoma commonly metastasizes to distant organs. However, metastasis to the urinary bladder is very uncommon. CASE PRESENTATION: Herein, we report a case of metachronous renal cell carcinoma with metastasis to the urinary bladder, left acetabulum, left rib, lungs, thyroid, right renal vein and inferior vena cava. The patient had undergone a left-sided radical nephrectomy 28 years ago. The pathological diagnosis of a fragment of the bladder tumor was consistent with Fuhrman grade 2 clear cell renal cell carcinoma. CONCLUSIONS: Although metachronous renal cell carcinoma after radical nephrectomy is rare, active surveillance should be still considered. Renal cell carcinoma has shown to unusually metastasize to the urinary bladder, a rarely reported organ of metastasis. Treatment options, such as immunotherapy, are available to patients with such metastasis and long-term survivorship can be achieved.
Subject(s)
Carcinoma, Renal Cell/secondary , Kidney Neoplasms/pathology , Neoplasms, Second Primary/secondary , Nephrectomy/methods , Urinary Bladder Neoplasms/secondary , Acetabulum/diagnostic imaging , Aged , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/secondary , Carcinoma, Renal Cell/diagnostic imaging , Carcinoma, Renal Cell/surgery , Humans , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/surgery , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/secondary , Magnetic Resonance Imaging , Male , Neoplasms, Second Primary/diagnostic imaging , Ribs/diagnostic imaging , Thyroid Neoplasms/diagnostic imaging , Thyroid Neoplasms/secondary , Time Factors , Tomography, X-Ray Computed , Urinary Bladder Neoplasms/diagnostic imaging , Urinary Bladder Neoplasms/surgeryABSTRACT
BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis (PM) from colorectal cancer (CRC) has been reported to substantially improve the prognosis and the quality of life of patients in comparison to systemic chemotherapy or palliative approaches. This study aimed to demonstrate the safety and feasibility of hepatectomy for metachronous liver metastases from CRC following CRS and HIPEC for PM on the basis of three case reports. CASE PRESENTATION: We describe three cases involving patients who underwent hepatectomy for metachronous liver metastases from CRC after CRS and HIPEC for PM. All patients underwent CRS and HIPEC after primary tumor resection, and hepatectomy was performed for the metachronous liver metastases after CRS and HIPEC. The hepatectomy procedures for cases 1, 2, and 3 were left hemihepatectomy and partial resection of S5, posterior sectionectomy, and left-lateral sectionectomy and partial resection of S5 and S8, respectively. Although adhesion of surrounding organs to the liver surface was observed on a broad level, dissections and hepatectomy could be performed safely. No recurrence was detected in cases 1 and 2 after hepatectomy. In case 3, liver metastases were detected from the time of the initial diagnosis of the primary tumor, and complete remission was achieved once with systemic chemotherapy. Although we performed hepatectomy for the recurrence of liver metastases after complete remission, early re-recurrence was observed after hepatectomy. CONCLUSIONS: Hepatectomy for metachronous liver metastases after CRS and HIPEC for PM could be a multi-modality treatment option for CRC recurrence.
Subject(s)
Chemotherapy, Cancer, Regional Perfusion/methods , Colorectal Neoplasms/therapy , Cytoreduction Surgical Procedures/methods , Hyperthermia, Induced/methods , Liver Neoplasms/surgery , Neoplasms, Second Primary/surgery , Peritoneal Neoplasms/therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colorectal Neoplasms/complications , Colorectal Neoplasms/pathology , Combined Modality Therapy , Female , Hepatectomy , Humans , Liver Neoplasms/complications , Liver Neoplasms/secondary , Male , Middle Aged , Neoplasms, Second Primary/complications , Neoplasms, Second Primary/secondary , Peritoneal Neoplasms/complications , Peritoneal Neoplasms/secondary , PrognosisSubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemoradiotherapy/methods , Chromosome Inversion , Chromosomes, Human, Pair 16/genetics , Leukemia, Myeloid, Acute/genetics , Neoplasms, Second Primary/genetics , Neuroendocrine Tumors/genetics , Adult , Capecitabine/administration & dosage , Female , Humans , Leukemia, Myeloid, Acute/pathology , Leukemia, Myeloid, Acute/therapy , Neoplasms, Second Primary/secondary , Neoplasms, Second Primary/therapy , Neuroendocrine Tumors/secondary , Neuroendocrine Tumors/therapy , Palliative Care , Prognosis , Temozolomide/administration & dosageABSTRACT
Renal cell carcinoma (RCC) metastasis to the adrenal gland, perirenal adipose tissue, and ureter on the contralateral side is rare. We report a case of solitary metachronous clear cell renal cell carcinoma (ccRCC) metastasis to the contralateral retroperitoneal adipose tissue, which was identified after radical nephrectomy. A patient had undergone retroperitoneal laparoscopic radical nephrectomy for RCC in the right kidney in December 2012. Postoperative pathological analysis showed Fuhrman grade I ccRCC, T1bN0M0. Three years after surgery, a solitary tumor of 1.0 × 1.0 cm was identified by an abdominal computed tomographic scan inside the retroperitoneal fat pad in front of the left posterior abdominal wall, without adhesion to the abdominal wall. The tumor was then completely resected by retroperitoneal laparoscopic resection. Pathological analysis showed that it was a metastasized lesion from a previous tumor. Nine months after surgery, there was no sign of recurrence confirmed by radiographic follow-up. Findings from this case indicate the unpredictability of dissemination of RCC. Our findings support a follow-up regimen that includes regular postoperative computed tomographic scans to identify early metastasis. To the best of our knowledge, this is the first reported case of contralateral retroperitoneal adipose metastasis after laparoscopic tumorectomy.
Subject(s)
Carcinoma, Renal Cell/secondary , Intra-Abdominal Fat/pathology , Kidney Neoplasms/secondary , Neoplasms, Second Primary/secondary , Nephrectomy/adverse effects , Retroperitoneal Neoplasms/secondary , Retroperitoneal Neoplasms/surgery , Carcinoma, Renal Cell/etiology , Humans , Kidney Neoplasms/etiology , Laparoscopy , Male , Middle Aged , Neoplasms, Second Primary/etiology , PrognosisABSTRACT
Staging is essential for scientific exchanges on colorectal cancer. Lack of a consensual definition for synchronous and metachronous metastases for colorectal cancer may introduce artifactual differences between epidemiological studies according to stage. We investigated how variations in the cutoff for the definition of synchronous metastases influenced the stage-specific distribution and incidence and the survival of stage IV patients. Between 2007 and 2013, a total of 4636 cases of colorectal adenocarcinoma were registered in the cancer registry of Burgundy. Age-standardized incidence by stage was estimated for each cutoff from 0 to 12 months, differentiating between synchronous and metachronous metastases. Net survival was calculated from the date of the diagnosis of metastasis. The incidence of stage IV colorectal cancer increased from 6.0/100 000 when considering metastases diagnosed within the first month to 7.1/100 000 when including metastases diagnosed until 12 months after the diagnosis of colorectal cancer. When the cutoff increased from 1 to 12 months, the relative variation in the proportion of cancers was +21% for stage IV, -12% for stage III, and -5% for stage II. Similarly, the 1-year net survival for metachronous group was over 10% higher than that for the synchronous group when the cutoff was over 5 months. An objective definition of the relevant cutoff to distinguish between synchronous and metachronous metastases is required for scientific epidemiologic exchanges. Survival in the metachronous group was significantly better than survival in the synchronous group when the cutoff between synchronous and metachronous was over 4 months after the primary diagnosis.
Subject(s)
Adenocarcinoma/pathology , Colorectal Neoplasms/pathology , Neoplasms, Multiple Primary/secondary , Neoplasms, Second Primary/secondary , Adenocarcinoma/epidemiology , Adenocarcinoma/mortality , Aged , Colorectal Neoplasms/epidemiology , Colorectal Neoplasms/mortality , Diagnosis, Differential , Female , Follow-Up Studies , France/epidemiology , Humans , Incidence , Male , Neoplasm Staging , Neoplasms, Multiple Primary/epidemiology , Neoplasms, Multiple Primary/mortality , Neoplasms, Second Primary/epidemiology , Neoplasms, Second Primary/mortality , Registries , Survival RateABSTRACT
BACKGROUND: Liver metastases from colorectal cancer are an important public health problem due to the increasing incidence of colorectal cancer worldwide. Synchronous colorectal liver metastasis has been associated with worse survival, but this prognosis is controversial. OBJECTIVE: The objective of this study was to evaluate the recurrence-free survival and overall survival between groups of patients with metachronous and synchronous colorectal hepatic metastasis. METHODS: This was a retrospective analysis of medical records of patients with colorectal liver metastases seen from 2013 to 2016, divided into a metachronous and a synchronous group. The Cox regression model and the Kaplan-Meier method with log-rank test were used to compare survival between groups. RESULTS: The mean recurrence-free survival was 9.75 months and 50% at 1 year in the metachronous group and 19.73 months and 63.3% at 1 year in the synchronous group. The mean overall survival was 20.00 months and 6.2% at 3 years in the metachronous group and 30.39 months and 31.6% at 3 years in the synchronous group. Patients with metachronous hepatic metastasis presented worse overall survival in multivariate analysis. The use of biological drugs combined with chemotherapy was related to the best overall survival prognosis. CONCLUSION: Metachronous colorectal hepatic metastasis was associated with a worse prognosis for overall survival. There was no difference in recurrence-free survival between metachronous and synchronous metastases.
Subject(s)
Colorectal Neoplasms/pathology , Liver Neoplasms/secondary , Neoplasms, Multiple Primary/secondary , Neoplasms, Second Primary/secondary , Colorectal Neoplasms/mortality , Colorectal Neoplasms/surgery , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Liver Neoplasms/mortality , Liver Neoplasms/surgery , Male , Middle Aged , Multivariate Analysis , Neoplasm Recurrence, Local , Neoplasms, Multiple Primary/mortality , Neoplasms, Multiple Primary/surgery , Neoplasms, Second Primary/mortality , Neoplasms, Second Primary/surgery , Retrospective Studies , Time FactorsABSTRACT
PURPOSE: We retrospectively evaluated the tumor regression after radiotherapy in combination with the immune checkpoint inhibitor nivolumab for metastatic melanoma. MATERIALS AND METHODS: We evaluated the extracranial metastatic melanoma lesions to which concomitant radiotherapy with nivolumab was administered from June 2015 to February 2017. Tumor volume and maximum diameter were measured at the time of pre-radiotherapy and best response, and the tumor reduction rate was assessed in two ways that our hospital adopts: tumor volume and diameter. RESULTS: Seven lesions in five patients were evaluated. The median time from the start of nivolumab treatment to the start of radiotherapy was 5 months (range 0-22 months). The objective response rate was 85.7% in the evaluation by tumor volume and 42.9% by maximum diameter of the tumor. The objective complete response rate was 28.6% in evaluation by tumor volume and 14.3% by maximum dia. The 1-year tumor control rate was 62.5%. The 1- and 2-year overall survival rate after nivolumab treatment were 75% and 50%, respectively. Two patients who obtained a complete response had presented with vitiligo. CONCLUSION: The combination of radiotherapy and nivolumab treatment produced favorable responses. Vitiligo may be correlated with a good response to concomitant radiotherapy with nivolumab.
Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Melanoma/drug therapy , Melanoma/radiotherapy , Neoplasms, Second Primary/drug therapy , Neoplasms, Second Primary/radiotherapy , Nivolumab/therapeutic use , Aged , Combined Modality Therapy/methods , Female , Humans , Male , Melanoma/secondary , Middle Aged , Neoplasms, Second Primary/secondary , Retrospective Studies , Survival Rate , Treatment Outcome , Tumor BurdenABSTRACT
ABSTRACT BACKGROUND: Liver metastases from colorectal cancer are an important public health problem due to the increasing incidence of colorectal cancer worldwide. Synchronous colorectal liver metastasis has been associated with worse survival, but this prognosis is controversial. OBJECTIVE: The objective of this study was to evaluate the recurrence-free survival and overall survival between groups of patients with metachronous and synchronous colorectal hepatic metastasis. METHODS: This was a retrospective analysis of medical records of patients with colorectal liver metastases seen from 2013 to 2016, divided into a metachronous and a synchronous group. The Cox regression model and the Kaplan-Meier method with log-rank test were used to compare survival between groups. RESULTS: The mean recurrence-free survival was 9.75 months and 50% at 1 year in the metachronous group and 19.73 months and 63.3% at 1 year in the synchronous group. The mean overall survival was 20.00 months and 6.2% at 3 years in the metachronous group and 30.39 months and 31.6% at 3 years in the synchronous group. Patients with metachronous hepatic metastasis presented worse overall survival in multivariate analysis. The use of biological drugs combined with chemotherapy was related to the best overall survival prognosis. CONCLUSION: Metachronous colorectal hepatic metastasis was associated with a worse prognosis for overall survival. There was no difference in recurrence-free survival between metachronous and synchronous metastases.
RESUMO CONTEXTO: As metástases hepáticas de câncer colorretal representam um importante problema de saúde pública devido à incidência crescente de câncer colorretal pelo mundo. A metástase hepática colorretal sincrônica está associada a pior sobrevida, no entanto, o pior prognóstico é assunto controverso. OBJETIVO: O objetivo do estudo foi avaliar a sobrevida livre de recorrência e a sobrevida global entre os grupos de pacientes com metástase hepática colorretal metacrônica e sincrônica. MÉTODO: Análise retrospectiva através de revisão de prontuários de pacientes com metástase hepática colorretal atendidos no período de 2013 a 2016, divididos em grupos metacrônico e sincrônico. Foram utilizados o modelo de regressão de Cox e o método de Kaplan-Meier com teste de Log-rank para comparação de sobrevida entre os grupos. RESULTADOS: A média de sobrevida livre de recorrência no grupo metacrônico foi de 9,75 meses e 50% em 1 ano, e no grupo sincrônico 19,73 meses e 63,3% em 1 ano. A média de sobrevida global no grupo metacrônico foi de 20,00 meses e 6,2% em 3 anos, e no grupo sincrônico 30,39 meses e 31,6% em 3 anos. Os pacientes com metástase hepática metacrônica apresentaram pior sobrevida global em análise multivariada. O uso de drogas biológicas associadas ao tratamento quimioterápico foi relacionado ao melhor prognóstico em sobrevida global. CONCLUSÃO: A metástase hepática colorretal metacrônica foi associada a pior prognóstico na sobrevida global. Não houve diferença na sobrevida livre de recorrência entre as metástases metacrônica e sincrônica.
Subject(s)
Humans , Male , Female , Colorectal Neoplasms/pathology , Neoplasms, Second Primary/secondary , Liver Neoplasms/secondary , Neoplasms, Multiple Primary/secondary , Time Factors , Colorectal Neoplasms/surgery , Colorectal Neoplasms/mortality , Multivariate Analysis , Retrospective Studies , Neoplasms, Second Primary/surgery , Neoplasms, Second Primary/mortality , Disease-Free Survival , Kaplan-Meier Estimate , Liver Neoplasms/surgery , Liver Neoplasms/mortality , Middle Aged , Neoplasm Recurrence, Local , Neoplasms, Multiple Primary/surgery , Neoplasms, Multiple Primary/mortalityABSTRACT
BACKGROUND: In this retrospective study, data from patients listed in the Korea Central Cancer Registry during 1993-2014 were analysed, to investigate the incidence and survival of second primary cancers (SPCs) after a diagnosis of primary peritoneal, epithelial ovarian, and fallopian tubal (POFT) cancer. METHODS: The standardised incidence ratio (SIR) and survival outcomes of patients with SPCs among POFT cancer survivors were analysed. RESULTS: Among 20,738 POFT cancer survivors, 798 (3.84%) developed SPCs, at an average interval of 5.50 years. SPC risk in POFT survivors (SIR, 1.29) was higher compared to the general population. The most high-risk type of SPC was leukaemia (3.07) followed by the lung and bronchus (1.80), colon (1.58), rectum and rectosigmoid junction (1.42), thyroid (1.34), and breast (1.26). In women aged < 60 years, cancer of the breast (1.30), ascending colon (2.26), and transverse colon (4.07) as SPCs increased. Up to 10 years after POFT cancer treatment, leukaemia risk increased, especially in those < 60 years, with serous histology, and with distant stage, which required aggressive chemotherapy. The median overall survival time was 12.8 years and 14.3 years in women with POFT cancer and SPCs, respectively. Thyroid and breast cancers were favourable prognostic markers among SPCs. CONCLUSIONS: The overall SPC risk increases in POFT cancer survivors, especially in those < 60 years. The cancer risk of breast and the proximal colon increase based on hereditary predisposition, while leukaemia likely develops from aggressive treatment. The median overall survival is favourable in POFT cancer survivors with SPCs.
Subject(s)
Carcinoma, Ovarian Epithelial , Fallopian Tube Neoplasms , Neoplasms, Second Primary , Peritoneal Neoplasms , Adult , Aged , Aged, 80 and over , Carcinoma, Ovarian Epithelial/epidemiology , Carcinoma, Ovarian Epithelial/mortality , Carcinoma, Ovarian Epithelial/pathology , Fallopian Tube Neoplasms/epidemiology , Fallopian Tube Neoplasms/mortality , Fallopian Tube Neoplasms/pathology , Female , Humans , Middle Aged , Neoplasms, Second Primary/epidemiology , Neoplasms, Second Primary/mortality , Neoplasms, Second Primary/secondary , Peritoneal Neoplasms/epidemiology , Peritoneal Neoplasms/mortality , Peritoneal Neoplasms/pathology , Retrospective StudiesABSTRACT
A 62-year-old female patient diagnosed with oesophageal adenocarcinoma underwent radical treatment consisting of neoadjuvant chemotherapy and oesophagectomy with no major complications. Eleven months later, she re-presented with a mass at one of the chest drain sites. A PET-CT scan and biopsy demonstrated this to be a single recurrence of the oesophageal adenocarcinoma. Excision of the metastatic lesion was considered as per metachronous single site metastasis. However, the operation was postponed due to acute kidney injury. Restaging after 6 weeks revealed progressive metastatic disease. The patient underwent palliative therapy and passed away soon after. Oesophageal cancer recurrence has a very poor prognosis, and factors such as the disease-free interval, site of recurrence and tumour pathological factors must be considered when stratifying for suitability for metastasectomy. A period of watchful waiting followed by restaging is essential to rule out patients with indolent metastatic disease.
Subject(s)
Adenocarcinoma/pathology , Esophageal Neoplasms/pathology , Neoplasms, Second Primary/secondary , Thoracic Neoplasms/secondary , Thoracic Wall/pathology , Adenocarcinoma/therapy , Biopsy , Drainage , Esophageal Neoplasms/therapy , Esophagectomy , Female , Humans , Middle Aged , Neoadjuvant Therapy , Neoplasms, Second Primary/diagnostic imaging , Neoplasms, Second Primary/therapy , Palliative Care , Positron Emission Tomography Computed Tomography , Thoracic Neoplasms/diagnostic imaging , Thoracic Neoplasms/therapy , Thoracic Wall/diagnostic imagingABSTRACT
Myoepithelial carcinoma (MC) is a rare, locally aggressive malignant neoplasm of the salivary glands. Only few evidences on its metastatic behavior are available in the literature. We herein present a unique case of MC of left parotid gland which metastasized to bilateral cavernous sinuses. The patient was successfully treated with palliative radiotherapy and chemotherapy.